Evidence map›Paper›PMID 36964441›Full record

ArticleNeurocritical care2023

Antipyretic Efficacy of Bromocriptine in Central Fever: an Exploratory Analysis.

Valeria Perez, Morgan McCreary, Lyndsay Sheperd, Tanna Nelson, Kartavya Sharma

Abstract read
PubMed Publisher
In one paragraph

Article in Neurocritical care, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Valeria PerezDepartment of Pharmacy, Texas Health Presbyterian Hospital, Dallas, TX, USA.
Morgan McCrearyDepartment of Neurology, UT Southwestern Medical Center, Dallas, TX, USA.
Lyndsay SheperdDepartment of Pharmacy, Texas Health Presbyterian Hospital, Dallas, TX, USA.
Tanna NelsonDepartment of Clinical Informatics Research, Texas Health Resources, Arlington, TX, USA.
Kartavya SharmaDepartment of Neurology, UT Southwestern Medical Center, Dallas, TX, USA. Kartavya.sharma@utsouthwestern.edu.ORCID http://orcid.org/0000-0003-0073-5915
Southwestern Medical Center · USTexas Health Dallas · USTexas Health Resources Foundation · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background'Central' fevers are thought to result from disruption of hypothalamic thermoregulatory pathways following severe brain injuries. Bromocriptine, due to its central dopamine receptor agonism, has been hypothesized to have antipyretic effect in this setting. However, clinical evidence for this off-label use is limited to a few case reports. In this retrospective cohort study, we analyzed the effect of bromocriptine administration on body temperature in acute brain injury patients with suspected central fever.

methodsWe screened a cohort of adult patients that received bromocriptine in the neurologic-intensive care unit of a tertiary care hospital between January 2018 and December 2021. Indication of central fever was ascertained by review of clinical documentation. A generalized additive mixed model (GAMM) was used to model temperature as a function of time relative to bromocriptine initiation. We adjusted for potential confounding due to the following covariates: temperature recording method (invasive vs surface), concurrent antipyretic administration within 8 h, and surface cooling device use within 4 h of temperature measurement. Temperature-time function was modeled using a cubic spline with k = 10 knots.

resultsA total of 33 patients were included in the analysis (14 women; mean age: 50 y, standard deviation 14 y). Median dose of bromocriptine was 7.5 mg (range 2.5-40) for a median of 13 d (range 5-160). Age and sex did not impact the function of temperature over time. Predicted temperatures were significantly (p < 0.05) higher by 0.4 °C with invasive compared to surface recording methods, lower by 0.2 °C in the presence of cooling device use and lower by 0.1 °C with concurrent antipyretic use. On adjusted analysis with the GAMM, there was decline (p < 0.05) in temperature following bromocriptine initiation by - 0.3 °C at 24 h, - 0.5 °C at 48 h, and - 0.7 °C at 72 h.

conclusionsBromocriptine use was associated with modest but statistically significant decline in temperature, with nadir at 72 h post initiation. The findings provide a data driven basis for prospective evaluation.

Indexed as

AntipyreticsAdultBody TemperatureBromocriptineFemaleFeverHumansMiddle AgedRetrospective StudiesAntipyreticsBromocriptineBrain injuriesBromocriptineCritical illnessFeverOff-label use

Identifiers

PMID36964441
OpenAlexW4360801666

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.